ClinicalTrials.gg
CompletedNCT03658343Updated Feb 21, 2025

T2* MRI Analysis for Sarcoma

An observational study in Radiotherapy, Magnetic Resonance Imaging and Sarcoma, sponsored by Bryan Allen. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-21.

Sponsored by Bryan Allen · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
8
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 958 studies in Sarcoma with a site in United States — 153 open to participants now, 242 under way, 4 of them phase 3. Sarcoma · United States.

Enrollment
89th of 100
8 · median 101
Started
2018
with 31 others
Observational
100 of 958
30 open now
Registered
653rd of 958
by date

Among the 958 studies in Sarcoma with a site in United States, this one is the 89th largest by enrollment of the 100 observational ones that give a count, is one of 32 that started in 2018, is one of 100 observational ones, and was the 653rd registered.

Sarcoma

1,610 studies on the registry are indexed under Sarcoma; 367 are open to participants now.

Browse Sarcoma studies →

Open to participants now

153 of the 958 studies in Sarcoma with a site in United States are open now. Recruiting first, the newest first:

148 more — sign in →

All 153 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 302 Sarcoma studies recruiting now, 192 (64%) set no upper age limit and 83 (27%) stop at 75 or younger; 94 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 958 studies in Sarcoma with a site in United States, or all of them as a file.
02

Study summary

T2* imaging is a method to identify labile iron pools in tumor cells. These iron pools may be linked to better treatment outcomes for specific types of therapy. This is a small pilot study to see if radiation therapy changes the amount of iron in a sarcoma tumor.

03

Conditions studied

  • Radiotherapy
  • Magnetic Resonance Imaging
  • Sarcoma

Browse trials for

Keywords

  • soft tissue sarcoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with pathologically confirmed sarcoma that have been recommended for standard of care radiation therapy

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed Sarcoma, by or excision
  • prescribed radiation therapy as per standard of care
  • treatment to begin within 5 weeks after surgery or biopsy
  • 0, 1, or 2
  • ability and willingness to provide

Exclusion criteria

Exclusion Criteria:

  • \< 18 years of age
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
8 participants (actual)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • T2* Imaging

    Participants undergo T2\* MRI imaging before beginning their course of radiation therapy and then after completing radiation therapy, about 2 weeks before their surgery.

    Diagnostic Test: T2* Imaging

Interventions

  • Diagnostic testT2* Imaging

    T2\* imaging sequences for MRI

    Also known as: magnetic resonance imaging, T2-star, T2* MRI

06

What researchers measure

Primary outcomes

  1. Change in ferric iron levels detected by T2* MRI

    Change from baseline in Fe3+ iron levels

    Time frame: baseline and 8 weeks

Secondary outcomes

  1. Change in ferrous iron levels detected by T2* MRI

    Change from baseline in Fe2+ iron levels

    Time frame: Baseline and 8 weeks

07

Study locations

1 site
  • Holden Comprehensive Cancer Center
    Iowa City, Iowa 52242, United States
08

References and documents

Individual participant data

Plan to share: Yes — Participants may opt in for individual data sharing; the data of those participants who have opted-in will be shared per plan.

Supporting information: Informed consent form

Time frame: After completion and analysis of data

Access criteria: Interested investigators should contact the study PI. Depending upon the data requested, an IRB application may be necessary.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2018 to primary completion in Feb 2022, 41 months.

Of 88 non-industry observational studies under Sarcoma, half reached primary completion within 72 months of starting (the median), counting those still running; a quarter within 47 and three quarters within 294. This study's 41 months is below that.

Counting every sponsor, half of 97 studies reached it within 66 months; a quarter within 42 and three quarters within 294.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 31, 2018
First posted
Sep 5, 2018
StartActual
Sep 18, 2018
Primary completionActual
Feb 25, 2022
CompletionActual
Feb 25, 2022
Last update
Feb 21, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 21, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03658343
Lead sponsor
Bryan Allen
Collaborators
Holden Comprehensive Cancer Center, National Cancer Institute (NCI)
Responsible party
Bryan Allen (Assistant Professor, University of Iowa) — Sponsor-investigator
First posted
Sep 5, 2018
Start date
Sep 18, 2018
Primary completion
Feb 25, 2022
Completion
Feb 25, 2022
Last update
Feb 21, 2025

Study contacts

Bryan Allen, MD, PhD
principal investigator · University of Iowa

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion